FOLH1 and neoplasm: Therefore, the tumor-to-bone marrow absorbed dose ratio of [177Lu]Lu-HTK03170 is actually inferior to that of [177Lu]Lu-PSMA-617, and potential bone marrow toxicity should be closely monitored when translating [177Lu]Lu-HTK03170 to the clinic.